Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Phase I Study of Novel SYK Inhibitor TAK-659 in Combination with R-CHOP for Front-Line Treatment of High Risk Diffuse Large B-Cell Lymphoma

Reem Karmali, Shuo Ma, Kelly D Foster, Jason Kaplan, Brett Alan Palmer, Xinlei Mi, Barbara Pro, Jane N. Winter, Leo I. Gordon

Blood (2021) 138 (Supplement 1): 3566.

https://doi.org/10.1182/blood-2021-144849

Published: 2021

Journal Articles

Safety and Efficacy of Ibrutinib Maintenance (I-M) Following Frontline Induction in Mantle Cell Lymphoma (MCL) with Sequential Assessment of Changes in NGS-MRD

Reem Karmali, Jeremy S. Abramson, Deborah M. Stephens, Jeffrey A Barnes, Jason Kaplan, Jane N. Winter, Shuo Ma, Juehua Gao, Adam M Petrich, Ephraim Hochberg, Tak Takvorian, Frank Kuhr, Lik Wee Lee, Valerie Nelson, Leo I. Gordon, Barbara Pro

Blood (2021) 138 (Supplement 1): 3530.

https://doi.org/10.1182/blood-2021-144707

Published: 2021

Journal Articles

Ibrutinib Maintenance (I-M) Following Intensive Induction in Mantle Cell Lymphoma (MCL): Efficacy, Safety and Changes in Minimal Residual Disease

Reem Karmali, MDMSc, Jeremy S Abramson, MD MMSc, Deborah M. Stephens, DO, Jeffrey A Barnes, MD PhD, Jason Kaplan, MD, Jane N. Winter, MD, Shuo Ma, MD PhD, Juehua Gao, MD PhD, Adam M Petrich, MD, Ephraim Hochberg, MD, Ronald Takvorian, Frank Kuhr, PhD, Valerie Nelson, MD MBA, Leo I. Gordon, MD, Barbara Pro, MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-137695

Published: 2020

Journal Articles

Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation

Reem Karmali, MD, Jeremy S. Abramson, MD MMSc, Deborah M. Stephens, DO, Jeffrey A. Barnes, MD PhD, Jason Kaplan, MD, Jane N. Winter, MD, Shuo Ma, MD PhD, Juehua Gao, MD PhD, Adam M. Petrich, MD, Ephraim Hochberg, MD, Ronald W. Takvorian, MD, Frank Kuhr, PhD, Valerie Nelson, MD MBA, Leo I. Gordon, MD, Barbara Pro, MD

Blood (2019) 134 (Supplement_1): 3990.

https://doi.org/10.1182/blood-2019-126920

Published: 2019

Journal Articles

Consolidation with Autologous Hematopoietic Cell Transplant in First Remission Improves Overall Survival in Younger Patients with Mantle Cell Lymphoma in the Rituximab Era

James Nathan Gerson, MD, Stefan Klaus Barta, MDMRCP,MS, Diego Villa, Alina S Gerrie, MD, Shaoying Li, MD, Jeffrey Medeiros, MD, Michael Wang, MD, Brian T. Hill, MD PhD, Yazeed Sawalha, MD, Francisco J. Hernandez-Ilizaliturri, MD, Shalin Kothari, MD, Julie M Vose, MD, Timothy S. Fenske, MD, Swapna Narayana Rao, MD, Kami J. Maddocks, MD, David A Bond, MD, Frederick Lansigan, MD, Timothy Burns, MD, Alexandra M Donovan, MD, Amitkumar Mehta, MD, Nishitha Reddy, MD MSCI, MBBS, Daniel J. Landsburg, MD, Martha Glenn, MD, David James Inwards, MD, Kay Ristow, Reem Karmali, MD MS, Jason Kaplan, MD, Elvira Umyarova, MD, Bhargavi Pulluri, MD, Jennifer E Amengual, MD, Jennifer Kimberly Lue, MD, Paolo Caimi, MD, Jonathon B Cohen, MDMS, Oscar Calzada, BS, Elizabeth Handorf, Jennifer Kelly Anderson, MD, Parv Chapani, Veronika Bachanova, MD PhD, Saurabh Rajguru, MD, Michael C Churnetski, BS, Catherine Diefenbach, Martin Bast, Alexandra E. Kovach, MD

Blood (2017) 130 (Supplement 1): 341.

https://doi.org/10.1182/blood.V130.Suppl_1.341.341

Published: 2017

Journal Articles

Multicenter Retrospective Study of Features and Outcomes of Patients with Intravascular DLBCL Treated at Academic Institutions within the United States

Blood (2017) 130 (Supplement 1): 377.

https://doi.org/10.1182/blood.V130.Suppl_1.377.377

Published: 2017

Journal Articles

Diffuse Large B-Cell Lymphomas Transformed from or with Concurrent Follicular Lymphoma Demonstrate Similar Clinical Outcomes As De-Novo Diffuse Large B-Cell Lymphomas, Except for Cases Harboring Double Hit Rearrangements

Amir Behdad, MD, Craig Boddy, MD, Angela Fought, Timothy Taxter, MD, Marissa Falkiewicz, BS, Daniel J. Landsburg, MD, Jane N. Winter, MD, Barbara Pro, MD, Leo I. Gordon, MD, Reem Karmali, MD MS, Jason Kaplan, MD

Blood (2017) 130 (Supplement 1): 828.

https://doi.org/10.1182/blood.V130.Suppl_1.828.828

Published: 2017

Journal Articles

A Phase (ph) 1b/2 Study of TAK-659, an Investigational Dual FLT-3 and SYK Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML)

Keith Pratz, MD, Mark J. Levis, MD, John C Morris, MD, Trisha Wise-Draper, MD PhD, Moshe Levy, MD, Dale L. Bixby, Patrick Burke, MD, Daniela Hernandez, MD, Kate Stumpo, BA, Karuppiah Kannan, Emily Sheldon-Waniga, PhD, Shining Wang, MD, Steven Zhang, PhD, Yaping Shou, MD PhD, Jessica K. Altman, MD, Jason Kaplan, MD, Olga Frankfurt, MD

Blood (2017) 130 (Supplement 1): 2622.

https://doi.org/10.1182/blood.V130.Suppl_1.2622.2622

Published: 2017

Journal Articles

Preliminary Results from an Ongoing Phase 1/2 Study of INCB053914, a Pan-Proviral Integration Sites for Moloney Virus (PIM) Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies

Michael Byrne, MD, William Donnellan, Manish R Patel, MD, Amer M. Zeidan, MD, Mohamad Cherry, MDMS, Maria R. Baer, MD, Amir T. Fathi, MD MD BS, Jason Kaplan, MD, Feng Zhou, Fred Zheng, MD, April M. Barbour, Michael R. Savona, MD

Blood (2017) 130 (Supplement 1): 2585.

https://doi.org/10.1182/blood.V130.Suppl_1.2585.2585

Published: 2017

Journal Articles

Phase 1 Study of TAK-659, an Investigational Reversible Dual SYK/FLT-3 Inhibitor, in Patients (Pts) with Lymphoma: Updated Results from Dose-Escalation and Expansion Cohorts

Jason Kaplan, MD, Leo I. Gordon, MD, Alessandro Rambaldi, MD Prof, Giuseppe Gritti, MD, Rakesh Popat, MD PhD, Howard A. Burris, MD, Manish R Patel, MD, Sumit Madan, MD, Ian Chau, MD, John A. Radford, MD, Swami P. Iyer, MD, Jaime Perez De Oteyza, MD, Pier Luigi Zinzani, MD, Shining Wang, MD, Emily Sheldon-Waniga, PhD, Kate Stumpo, BA, Yaping Shou, MD PhD, Cecilia Carpio, MD, Francesc Bosch, MD

Blood (2017) 130 (Supplement 1): 1554.

https://doi.org/10.1182/blood.V130.Suppl_1.1554.1554

Published: 2017

NARROW

Phase I Study of Novel SYK Inhibitor TAK-659 in Combination with R-CHOP for Front-Line Treatment of High Risk Diffuse Large B-Cell Lymphoma

Safety and Efficacy of Ibrutinib Maintenance (I-M) Following Frontline Induction in Mantle Cell Lymphoma (MCL) with Sequential Assessment of Changes in NGS-MRD

Ibrutinib Maintenance (I-M) Following Intensive Induction in Mantle Cell Lymphoma (MCL): Efficacy, Safety and Changes in Minimal Residual Disease

Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation

Consolidation with Autologous Hematopoietic Cell Transplant in First Remission Improves Overall Survival in Younger Patients with Mantle Cell Lymphoma in the Rituximab Era

Multicenter Retrospective Study of Features and Outcomes of Patients with Intravascular DLBCL Treated at Academic Institutions within the United States

Diffuse Large B-Cell Lymphomas Transformed from or with Concurrent Follicular Lymphoma Demonstrate Similar Clinical Outcomes As De-Novo Diffuse Large B-Cell Lymphomas, Except for Cases Harboring Double Hit Rearrangements

A Phase (ph) 1b/2 Study of TAK-659, an Investigational Dual FLT-3 and SYK Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML)

Preliminary Results from an Ongoing Phase 1/2 Study of INCB053914, a Pan-Proviral Integration Sites for Moloney Virus (PIM) Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies

Phase 1 Study of TAK-659, an Investigational Reversible Dual SYK/FLT-3 Inhibitor, in Patients (Pts) with Lymphoma: Updated Results from Dose-Escalation and Expansion Cohorts

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only